- Home
- RARE vs CXW Comparison
RARE vs CXW Comparison
Compare RARE & CXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | CXW |
|---|---|---|
| Founded | 2010 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2014 | 1997 |
Fundamental Metrics
Financial Performance| Metric | RARE | CXW |
|---|---|---|
| Price | $23.86 | $18.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 2 |
| Target Price | ★ $73.11 | $34.00 |
| AVG Volume (30 Days) | ★ 2.7M | 917.2K |
| Earning Date | 02-13-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.55 |
| EPS | N/A | ★ 1.00 |
| Revenue | $630,598,000.00 | ★ $2,086,522,000.00 |
| Revenue This Year | $20.17 | $12.51 |
| Revenue Next Year | $19.10 | $15.41 |
| P/E Ratio | ★ N/A | $18.54 |
| Revenue Growth | ★ 20.63 | 5.72 |
| 52 Week Low | $18.41 | $15.95 |
| 52 Week High | $46.50 | $23.54 |
Technical Indicators
Market Signals| Indicator | RARE | CXW |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 42.12 |
| Support Level | $23.26 | $18.27 |
| Resistance Level | $25.82 | $18.81 |
| Average True Range (ATR) | 1.02 | 0.57 |
| MACD | 0.43 | -0.14 |
| Stochastic Oscillator | 48.69 | 16.93 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CXW CoreCivic Inc.
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.